UPDATE ON TREATMENTS OF PERIPHERAL T CELL LYMPHOMA
3 AGGRESSIVE TYPES:
==================
1. PTLC- NOS
2. AITL: AngioImmunoblastic
3ALCL (Anaplastic large cell (ALK +) 6% AND alk NEGATIVE
CD30 , t(2,5)(p23,q25)
---------------------------------------------------------------------------------
1 Peripheral T cell lymphoma not otherwise specified
-PET
-Gene Profiling
treat it with EPOCH (CHOEP) or Etoposide based regimen followed by transplant
consider Romidepsin (upfront in Europe)
followed by Gemcitabine, Navelbine (Doxil)
Europeans give ACVBP +/- Romidepsin (Vindesin not available in the US)
refractory disease" FDA has released 3 drugs, their role and position is being evaluated"
=============
Romidepsin
Pralatrexate
CD30 positive - BRENTUXIMAB VEDOITIN
----------------------------------------------------------------------------------------------
2. some T cell lymphoma are clearly Indolent i.e Mycosis Fungoides (MF)
-------------------------------------------------------------------------------
3. Anaplastic Large cell Lymphoma
ALK negative
for Europeans ACVBP followed by transplant
USA, same paradigm as in PTCL NOS
FOR ALK POSITIVE -- CHOP ALONE IS THE BEST NO TRANSPLANT (NO ETOPOSIDE NEEDED) (THE GERMAN STUDY WAS RETROSPECTIVE )
CRIZOTINIB
PRALATREXATE AND ROMIDEPSIN HAVE BEEN USED IN CLINICAL TRIAL
---------------------------------------------------------------------------------------------------------
4. ANGIOIMMUNOBLASTIC
STEROIDS
SOME CLAIM CYCLOSPORINE (PARTICULARLY WHEN HEMOLYTIC ANEMIA)
IN EUROPE CHOP-ROMIDEPSIN
IN USA, GEMZAR
FOR THOSE WITH A COMPONENT OF CD20 POSITIVE, RITUXAN +STEROID
WHATEVER YOU DO, DON'T GIVE ADRIAMYCIN!
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
No comments:
Post a Comment